Floxin: profile and news






BAD BUGS, NO DRUGS ; Our Dwindling Pill Arsenal Can't Fight New ...  Mar 2, 2006
Now the newer quinolone class of antibiotics such as Cipro and Floxin, which became the drugs of choice, are being defeated in the US and in Australia, Canada ... - International News Service,

First-Time Generic Approvals: Metaglip, Zofran ODT, Floxin Otic  Nov 22, 2005
...formulation of ofloxacin 0.3% otic solution (made by Hi Tech Pharmacal Company, Inc., Apotex, Inc., and Bausch & Lomb, Inc.; brand name Floxin Otic, made by ... - Medscape (subscription)

Apotex Receives Final Approval for Ofloxacin Otic 0.3%  Nov 30, 2005
The order also prevents Daiichi from launching an authorized generic version of its Floxin(R) product until final judgment is entered in the case. ... - Genetic Engineering News,

New Medicare drug benefit creates confusion  Sep 25, 2005
But quinolone-type antibiotics (Levaquin, Cipro, Floxin, Noroxin, Tequin) may trigger nervousness, confusion, dizziness, depression or even psychosis. ... - Houston Chronicle,

COMPANY OF THE YEAR: Johnson & Johnson  Sep 15, 2005
...period in 2004. Combined sales of the anti-infectives Levaquin and Floxin grew 12.8% in 2004 compared with 2003. Combined sales ... - Med Ad News (subscription),

Many meds don't mix with the sun  Sep 21, 2005
Flagyl), minocycline (Minocin), moxifloxacin (Ave-lox), nalidixic acid (NegGram), norfloxacin (Noroxin), ofloxacin (Floxin), oxytetracycline (Terra-mycin ... - Pioneer Press,

Free Health Stuff for Your Kids  Aug 19, 2005
Your Pediatrician may also have sample of topical antibiotics, such as Oculfox, Vigamox and Ciloxan for pink-eye, Floxin, Cipro-DEX and Cipro HC for swimmers ... - pediatrics.about.com

Hi-Tech Pharmacal Reports a 32% Sales Increase and an 83% EPS ...  Jul 13, 2005
...ophthalmic solution USP, 0.5%, equivalent to Santen's Quixin(R) Ophthalmic Solution, 0.5%, and Ofloxacin otic solution, equivalent to Daiichi's Floxin(R) otic ... - Genetic Engineering News <**results**>

Free Health Stuff for Your Kids  Jun 21, 2005
Your Pediatrician may also have sample of topical antibiotics, such as Oculfox, Vigamox and Ciloxan for pink-eye, Floxin, Cipro-DEX and Cipro HC for swimmers ... - pediatrics.about.com

Free Health Stuff for Your Kids  Jun 21, 2005
Your Pediatrician may also have sample of topical antibiotics, such as Oculfox, Vigamox and Ciloxan for pink-eye, Floxin, Cipro-DEX and Cipro HC for swimmers ... - pediatrics.about.com

Cipro, Levaquin, Floxin, Tequin, Zagam, Factive, Trovan, Just  Apr 6, 2005
People who have been physically damaged by taking: Cipro, Levaquin, Floxin, Tequin, Avelox, Vigamox, Quixin, Ciprodex, Ocuflox, Ciloxan, etc. ... - Khalsa News Network,

Report: Sankyo eyes drugs merger  Feb 20, 2005
States. Products they sell include antibacterial ear drop Floxin Otic and Camptosar, a colon cancer drug co-marketed with Pfizer Inc. ... - CNN International


Other information


Indication
For the treatment of Bacterial infection of Respiratory tract, UTI, Uncomplicated Cystitis in females, GI, Chronic Bacterial Prostatitis, CNS, Immuno compromised patients, Skin, Bone and Joint Infections, Uncomplicated cervical and urethral gonorrhea

Pharmacology
Ciprofloxacin, a broad-spectrum antiinfective agent of the fluoroquinolone class, is used to treat gram-negative infections, sexually transmitted diseases, mycobacterial infections, corneal ulcers, and bacterial conjunctivitis.

Mechanism Of Action
Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive organisms. Ciprofloxacin inhibits bacterial DNA gyrase, an enzyme responsible for counteracting excessive supercoiling of DNA during replication or transcription. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials.

Drug Category
Anti-Infectives; Quinolones; ATC:J01MA02; ATC:S01AX13; ATC:S03AA07

Brand Names/Synonyms
Bacquinor; Baycip; Bernoflox; CIPROFLOXACIN HCL; Ciflox; Cifloxin; Ciloxan; Ciprinol; Cipro; Cipro I.V.; Cipro Xl; Cipro Xr; Ciprobay; Ciprocinol; Ciprodar; Ciprofloxacin; Ciprofloxacin Base; Ciprofloxacin Dihydrochloride; Ciprofloxacin Hydrochloride; Ciprofloxacin Monohydrochloride; Ciprofloxacina; Cipromycin; Ciproquinol; Ciproxan; Ciproxin; Flociprin; Floxin; Floxin Otic; Floxin in Dextrose 5%; Ocuflox; Ofloxacin; Proquin Xr; Septicide; Velomonit

Dosage Forms
LIQUID; OINTMENT; SOLUTION; SUSPENSION; TABLET; TABLET (COMBINED RELEASE); TABLET (EXTENDED-RELEASE)

Absorption
70-80%

Interactions
-->Interactions for Ciprofloxacin:

Caffeine

Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.

Cyclosporine

Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Glyburide

The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.

Histamine H2-receptor antagonists

Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.

Methotrexate

Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.

Multivalent Cation-Containing Products

Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired. Proquin XR should be administered at least 4 hours before or 2 hours after these products. This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.

Non-steroidal anti-inflammatory drugs (but not aspirin)

These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.

Omeprazole

The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion. Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..

Phenytoin

Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.

Probenecid

Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.

Theophylline

As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.

Warfarin

Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored.



Chemical IUPAC Name
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-3-carboxylicacid

Chemical Formula
C17H18FN3O3

Half Life
4 hours

Drug Type
Approved Drug

# Accession No
APRD00424

CAS Registry Number
85721-33-1

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org